DYN Q3 2017 Earnings — Dyne Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

DYNDyne Therapeutics, Inc.

$3B

Q3 2017 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$182M-24.5% YoY

Gross Profit

-$605M-332.4% margin

Operating Income

$58M31.9% margin

Net Income

-$133M-73.1% margin

EPS (Diluted)

$-0.82

QoQ Revenue Growth

+0.6%

Cash Flow

Operating Cash Flow

$271M

Free Cash Flow

$271M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$12.0B

Total Liabilities

$10.0B

Stockholders' Equity

$2.0B

Cash & Equivalents

$613M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$182M	$241M	-24.5%
Gross Profit	-$605M	-$419M	-44.4%
Operating Income	$58M	-$117M	+149.6%
Net Income	-$133M	-$249M	+46.6%